Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-Methylbenzo[C][1,2,5]Oxadiazole1-Oxide SCHEMBL6199005 | 0.85 | NPSR1 (0.47) | CA12CA2CA9NPSR1GRIA2 | |
| SCHEMBL11741140 | 0.82 | CA12 (0.47) | CA12CA2CA9NPSR1GRIA2 | |
| SCHEMBL7747611 | 0.77 | CA12 (0.56) | CA12CA2CA9NPSR1GRIA2 | |
| SCHEMBL7752547 | 0.77 | CA12 (0.56) | CA12CA2CA9NPSR1GRIA2 | |
| SCHEMBL1420493 | 0.77 | CA12 (0.56) | CA12CA2CA9NPSR1GRIA2 | |
| SCHEMBL19294776 | 0.77 | CA12 (0.51) | CA12CA2CA9NPSR1GRIA2 | |
| SCHEMBL10574018 | 0.77 | CA12 (0.51) | CA12CA2CA9ALDH1A1MAPT | |
| SCHEMBL8686150 | 0.76 | GRIA2 (0.51) | CA12CA2CA9NPSR1GRIA2 | |
| SCHEMBL10576406 | 0.74 | CA12 (0.74) | CA12CA2CA9NPSR1MAPT | |
| SCHEMBL10572650 | 0.73 | CA12 (0.51) | CA12CA2CA9GRIA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114038-A1 | Drugs Derived from Diclofenac Containing No-Donor Heterocycles, Composition and Method of Inflammation Treatment | PEDRAZZOLI JOSE | 2008-05-15 | — | — | US | disclosed |
| WO-2006042387-A1 | DRUGS DERIVED FROM DICLOFENAC CONTAINING NO-DONOR HETEROCYCLES, COMPOSITION AND METHOD OF INFLAMMATION TREATMENT | CMAX OTIMIZACÃO DE RESULTADOS S C LTDA (BR) | 2006-04-27 | — | — | WO | disclosed |
| US-4866175-A | REACTING BENZOFUROXAN WITH MALONIC ESTER, CYANO(ESTER OR AMIDE), KETO(ESTER OR AMIDE), DIKETONE, MALONONITRILE, OR NITRO COMPOUND | RESEARCH CORPORATION (US) | 1989-09-12 | — | — | US | disclosed |
| US-4343942-A | BACTERICIDES | RESEARCH CORPORATION (US) | 1982-08-10 | — | — | US | disclosed |
| US-4001410-A | MICROBIOCIDES AND LIVESTOCK GROWTH PROMOTERS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
| US-3980779-A | ANTIMICROBIAL ACTIVITY | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114038-A1 | Drugs Derived from Diclofenac Containing No-Donor Heterocycles, Composition and Method of Inflammation Treatment | PTGS1, PTGS2, PTGES | CA12 3542/4885CA2 873/4885CA9 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.